Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Liver Diseases

  Free Subscription


Articles published in J Clin Oncol

Retrieve available abstracts of 12 articles:
HTML format



Single Articles


    December 2021
  1. SALEM R
    Hepatic Arterial Infusion Chemotherapy for Large Hepatocellular Carcinoma: Ready for Prime Time?
    J Clin Oncol. 2021 Dec 2:JCO2102392. doi: 10.1200/JCO.21.02392.
    PubMed    


    October 2021
  2. LI QJ, He MK, Chen HW, Fang WQ, et al
    Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin Versus Transarterial Chemoembolization for Large Hepatocellular Carcinoma: A Randomized Phase III Trial.
    J Clin Oncol. 2021 Oct 14:JCO2100608. doi: 10.1200/JCO.21.00608.
    PubMed     Abstract available


    September 2021
  3. RAYSON D
    Cardio-Oncology.
    J Clin Oncol. 2021;39:2962-2963.
    PubMed    


    July 2021
  4. KELLEY RK, Sangro B, Harris W, Ikeda M, et al
    Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study.
    J Clin Oncol. 2021 Jul 22:JCO2003555. doi: 10.1200/JCO.20.03555.
    PubMed     Abstract available


    June 2021
  5. QIN S, Bi F, Gu S, Bai Y, et al
    Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial.
    J Clin Oncol. 2021 Jun 29:JCO2100163. doi: 10.1200/JCO.21.00163.
    PubMed     Abstract available


    November 2020
  6. GORDAN JD, Kennedy EB, Abou-Alfa GK, Beg MS, et al
    Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline.
    J Clin Oncol. 2020 Nov 16:JCO2002672. doi: 10.1200/JCO.20.02672.
    PubMed     Abstract available


    September 2020
  7. TANG W, Ren L, Liu T, Ye Q, et al
    Bevacizumab Plus mFOLFOX6 Versus mFOLFOX6 Alone as First-Line Treatment for RAS Mutant Unresectable Colorectal Liver-Limited Metastases: The BECOME Randomized Controlled Trial.
    J Clin Oncol. 2020;38:3175-3184.
    PubMed     Abstract available


  8. CHAO C, Bhatia S, Xu L, Cannavale KL, et al
    Chronic Comorbidities Among Survivors of Adolescent and Young Adult Cancer.
    J Clin Oncol. 2020;38:3161-3174.
    PubMed     Abstract available


    July 2020
  9. FINN RS, Ikeda M, Zhu AX, Sung MW, et al
    Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma.
    J Clin Oncol. 2020 Jul 27:JCO2000808. doi: 10.1200/JCO.20.00808.
    PubMed     Abstract available


    May 2020
  10. HIYAMA E, Hishiki T, Watanabe K, Ida K, et al
    Outcome and Late Complications of Hepatoblastomas Treated Using the Japanese Study Group for Pediatric Liver Tumor 2 Protocol.
    J Clin Oncol. 2020 May 18:JCO1901067. doi: 10.1200/JCO.19.01067.
    PubMed     Abstract available


  11. LEVY EB, Fiel MI, Hamilton SR, Kleiner DE, et al
    State of the Art: Toward Improving Outcomes of Lung and Liver Tumor Biopsies in Clinical Trials-A Multidisciplinary Approach.
    J Clin Oncol. 2020;38:1633-1640.
    PubMed     Abstract available


    October 2019
  12. MODEST DP, Martens UM, Riera-Knorrenschild J, Greeve J, et al
    FOLFOXIRI Plus Panitumumab As First-Line Treatment of RAS Wild-Type Metastatic Colorectal Cancer: The Randomized, Open-Label, Phase II VOLFI Study (AIO KRK0109).
    J Clin Oncol. 2019 Oct 14:JCO1901340. doi: 10.1200/JCO.19.01340.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Liver Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: